Dapagliflozin for Heart Failure: is It a Class effect?

References

• FDA . FDA news release: FDA approves new treatment for a type of heart failure (2020). https://www.fda.gov/news-events/press-announcements/fda-approves-new-treatment-type-heart-failure
   Google Scholar
• McMurray JJV , SolomonSD, InzucchiSEet al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N. Engl. J. Med., 381(21), 1995–2008 (2019).
   PubMed Web of Science ®Google Scholar
• Martinez FA , SerenelliM, NicolauJCet al. Efficacy and safety of dapagliflozin in heart failure with reduced ejection fraction according to age: insights from DAPA-HF. Circulation, 141(2), 100–111 (2020).
   PubMed Web of Science ®Google Scholar
• Petrie MC , VermaS, DochertyKFet al. Effect of dapagliflozin on worsening heart failure and cardiovascular death in patients with heart failure with and without diabetes. JAMA, 323(14), 1353–1368 (2020).
   PubMed Web of Science ®Google Scholar
• Docherty KF , JhundPS, InzucchiSEet al. Effects of dapagliflozin in DAPA-HF according to background heart failure therapy. Eur. Heart J., 41(25), 2379–2392 (2020).
   PubMed Web of Science ®Google Scholar
• Kosiborod MN , JhundPS, DochertyKFet al. Effects of dapagliflozin on symptoms, function, and quality of life in patients with heart failure and reduced ejection fraction: results from the DAPA-HF trial. Circulation, 141(2), 90–99 (2020).
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov . Dapagliflozin evaluation to improve the lives of patients with preserved ejection fraction heart failure (DELIVER trial) (2018). https://clinicaltrials.gov/ct2/show/NCT03619213?term=dapagliflozin&cond=heart+failure+with+preserved+ejection+fraction&rank=1
   Google Scholar
• Rådholm K , FigtreeG, PerkovicVet al. Canagliflozin and heart failure in Type 2 diabetes mellitus: results from the CANVAS program. Circulation, 138(5), 458–468 (2018).
   PubMed Web of Science ®Google Scholar
• Perkovic V , JardineMJ, NealBet al. Canagliflozin and renal outcomes in Type 2 diabetes and nephropathy. N. Engl. J. Med., 380(24), 2295–2306 (2019).
   PubMed Web of Science ®Google Scholar
• Fitchett D , ZinmanB, WannerCet al. Heart failure outcomes with empagliflozin in patients with Type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME® trial. Eur. Heart J., 37(19), 1526–1534 (2016).
   PubMed Web of Science ®Google Scholar
• Packer M , ButlerJ, FilippatosGSet al. Evaluation of the effect of sodium-glucose co-transporter 2 inhibition with empagliflozin on morbidity and mortality of patients with chronic heart failure and a reduced ejection fraction: rationale for and design of the EMPEROR-Reduced trial. Eur. J. Heart Fail., 21(10), 1270–1278 (2019).
   PubMed Web of Science ®Google Scholar
• Anker SD , ButlerJ, FilippatosGSet al. Evaluation of the effects of sodium-glucose co-transporter 2 inhibition with empagliflozin on morbidity and mortality in patients with chronic heart failure and a preserved ejection fraction: rationale for and design of the EMPEROR-Preserved trial. Eur. J. Heart Fail., 21(10), 1279–1287 (2019).
   PubMed Web of Science ®Google Scholar
• Abraham WT , PonikowskiP, BrueckmannMet al. Rationale and design of the EMPERIAL-Preserved and EMPERIAL-Reduced trials of empagliflozin in patients with chronic heart failure. Eur. J. Heart Fail., 21(7), 932–942 (2019).
   PubMed Web of Science ®Google Scholar
• Boehringer Ingelheim – Press Release . Boehringer Ingelheim and Lilly provide update on Jardiance®Phase III exercise ability studies in chronic heart failure (2019). https://www.boehringer-ingelheim.us/press-release/boehringer-ingelheim-and-lilly-provide-update-jardiance-phase-iii-exercise-ability
   Google Scholar
• Cannon CP , McGuireDK, PratleyRet al. Design and baseline characteristics of the eValuation of ERTugliflozin effIcacy and safety cardiovascular outcomes trial (VERTIS-CV). Am. Heart J., 206, 11–23 (2018).
   PubMed Web of Science ®Google Scholar
• Cannon CP , KumbhaniDJ. Evaluation of ertugliflozin efficacy and safety cardiovascular outcomes trial. Presented at: American Diabetes Association Virtual Scientific Sessions (2020). https://www.acc.org/latest-in-cardiology/clinical-trials/2020/06/16/11/24/vertis
   Google Scholar
• Zelniker TA , WiviottSD, RazIet al. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in Type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet, 393(10116), 31–39 (2019).
   PubMedGoogle Scholar
• Vaduganathan M , JanuzziJLJr. Preventing and treating heart failure with sodium-glucose co-transporter 2 inhibitors. Am. J. Cardiol., 124(Suppl. 1), S20–S27 (2019).
   PubMedGoogle Scholar
• Couselo-Seijas M , Agra-BermejoRM, FernándezALet al. High released lactate by epicardial fat from coronary artery disease patients is reduced by dapagliflozin treatment. Atherosclerosis, 292, 60–69 (2020).
   PubMed Web of Science ®Google Scholar
• Ghosh RK , GhoshGC, GuptaMet al. Sodium glucose co-transporter 2 inhibitors and heart failure. Am. J. Cardiol., 124(11), 1790–1796 (2019).
   PubMed Web of Science ®Google Scholar
• Brown E , RajeevSP, CuthbertsonDJ, WildingJPH. A review of the mechanism of action, metabolic profile and haemodynamic effects of sodium-glucose co-transporter-2 inhibitors. Diabetes Obes. Metab., 21(Suppl. 2), 9–18 (2019).
   PubMedGoogle Scholar
• Jensen J , OmarM, KistorpCet al. Empagliflozin in heart failure patients with reduced ejection fraction: a randomized clinical trial (Empire HF). Trials, 20(1), 374 (2019).
   PubMedGoogle Scholar
• ClinicalTrials.gov . ERtugliflozin triAl in DIabetes With Preserved or Reduced ejeCtion FrAcTion mEchanistic Evaluation in Heart Failure (ERADICATE-HF). (2018). https://www.clinicaltrials.gov/ct2/show/NCT03416270
   Google Scholar
• Kato ET , SilvermanMG, MosenzonOet al. Effect of dapagliflozin on heart failure and mortality in Type 2 diabetes mellitus. Circulation, 139(22), 2528–2536 (2019).
   PubMed Web of Science ®Google Scholar
• Patorno E , PawarA, FranklinJMet al. Empagliflozin and the risk of heart failure hospitalization in routine clinical care. Circulation, 139(25), 2822–2830 (2019).
   PubMed Web of Science ®Google Scholar
• Böhm M , SlawikJ, BrueckmannMet al. Efficacy of empagliflozin on heart failure and renal outcomes in patients with atrial fibrillation: data from the EMPA-REG OUTCOME trial. Eur. J. Heart Fail., 22(1), 126–135 (2020).
   PubMed Web of Science ®Google Scholar
• Felker GM . Building the foundation for a new era of quadruple therapy in heart failure. Circulation, 141(2), 112–114 (2020).
   PubMed Web of Science ®Google Scholar